Shortages of drugs, including chemotherapeutics, are increasingly common in the USA, and compromise patient care, delay clinical trials and are associated with substantial financial costs. The recent shortage of vincristine, a chemotherapeutic used for most children with cancer and countless adult patients, presents a particularly vexing challenge. Drug shortages can cause patients unnecessary anxiety and challenge clinicians to ration lifesaving medications for which no alternative agent exists. We provide an overview of this problem and discuss potential solutions.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A microbial supply chain for production of the anti-cancer drug vinblastine
Nature Open Access 31 August 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
ASH Clinical News. Vincristine shortages may continue through December. ashclinicalnews.org https://www.ashclinicalnews.org/online-exclusives/vincristine-shortages-may-continue-december/ (2019).
US Food & Drug Administration. Drug shortages: root causes and potential solutions. fda.gov https://www.fda.gov/media/131130/download (2019).
Vizient. Drug Shortages and Labor Costs — Measuring a hidden cost of drug shortages on U.S. hospitals. vizientinc.com https://www.vizientinc.com/-/media/Documents/SitecorePublishingDocuments/Public/VZDrugShortagesLaborCost_FullReport.pdf (2019).
Rosenberg M. What do FDA data tell us about the scope and scale of drug shortages? duke.edu https://healthpolicy.duke.edu/sites/default/files/atoms/files/duke-fda_drug_shortages_presentation_slides__0.pdf (2018).
NORC at the University of Chicago. Recent trends in hospital drug spending and manufacturer shortages. aha.org https://www.aha.org/system/files/2019-01/aha-drug-pricing-study-report-01152019.pdf (2019).
Institute for Safe Medication Practices. A shortage of everything except errors: Harm associated with drug shortages. ismp.org https://www.ismp.org/resources/shortage-everything-except-errors-harm-associated-drug-shortages (2012).
[No authors listed]. Drug shortages roundtable: minimizing the impact on patient care. Am. J. Health. Syst. Pharm. 75, 816–820 (2018).
Edney, A. Facing cancer drug shortages, U.S. relies on banned chinese plant. Bloomberg.com http://www.bloomberg.com/news/articles/2016-07-22/facing-cancer-drug-shortage-u-s-relies-on-banned-chinese-plant (2019).
Metzger, M. L., Billett, A. & Link, M. P. The impact of drug shortages on children with cancer — the example of mechlorethamine. N. Engl. J. Med. 367, 2461–2463 (2012).
Fox, E. R., Sweet, B. V. & Jensen, V. Drug shortages: a complex health care crisis. Mayo Clin. Proc. 89, 361–373 (2014).
Salazar, G. E. et al. The impact of chemotherapy shortages on COG and local clinical trials: a report from the Children’s Oncology Group. Pediatr. Blood Cancer 62, 940–944 (2015).
Woodcock, J. To help reduce drug shortages, we need manufacturers to sell quality — not just medicine. fda.gov https://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-and-experts/help-reduce-drug-shortages-we-need-manufacturers-sell-quality-not-just-medicine (2019).
Dill, S. & Ahn, J. Drug shortages in developed countries — reasons, therapeutic consequences, and handling. Eur. J. Clin. Pharmacol. 70, 1405–1412 (2014).
Unguru, Y. et al. Chemotherapy and supportive care agents are essential medicines for children with cancer. JAMA Pediatr. 173, 477–484 (2019).
Congress.gov. S.2723 — Mitigating Emergency Drug Shortages Act. congress.gov https://www.congress.gov/bill/116th-congress/senate-bill/2723/text (2019).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
University of Utah Health is a member of a Group Purchasing Organization, Vizient. The University of Utah Drug Information Service (UUDIS) has a contract with Vizient to provide them with information on drug shortages. The value of this contract is <5% of the budget for this nine-person unit. No funds are paid to E.R.F. The UUDIS provides all of the content for the American Society of Health-System Pharmacists (ASHP) drug-shortage website at www.ashp.org/shortages. In the past 36 months, E.R.F. has received partial travel support (no honoraria) to provide continuing education or presentations from The Idaho Society of Health System Pharmacists, the Massachusetts Society of Health System Pharmacists, the Anesthesia Patient Safety Foundation, the American Society of Anesthesia, the ASHP, the University of Illinois at Chicago, the National Academies of Sciences, Engineering, and Medicine, the FDA, the Mayo Clinic, the European Cooperation in Science & Technology (COST), the Immunoglobulin National Society, the Association of Critical Care Transport and the Center for Infectious Disease Research and Policy. E.R.F. has also had an unpaid advisory position at CivicaRx. Y.U. declares no competing interests.
Rights and permissions
About this article
Cite this article
Fox, E.R., Unguru, Y. Oncology drug shortages in the USA — business as usual. Nat Rev Clin Oncol 17, 128–129 (2020). https://doi.org/10.1038/s41571-019-0318-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0318-x
This article is cited by
-
Engineered yeast brews precursors of anticancer drug vinblastine
Nature (2022)
-
Exploring the barriers related to the healthcare system in implementing quality intravenous chemotherapy: a qualitative study
Supportive Care in Cancer (2022)
-
A microbial supply chain for production of the anti-cancer drug vinblastine
Nature (2022)
